Tag Archive for: R&D

“We plan to continue investing in our transformation with a focus on building commercial capabilities in oncology and working towards registrational trials,” said CEO and Co-Founder Ugur Sahin.

Q4 and full-year 2022 financial statements have revealed several companies slashing I-O pipelines. Here are just some of the factors at play.

Bayer AG plans to spend $1 billion on drug research and development in the U.S. this year as it works to double its sales in the country by the end of the decade, Bayer’s top U.S. pharmaceutical executive told Reuters.

The Danish drugmaker will migrate most of its U.S.-based research work to the new R&D hub as part of the expansion.

Dealing with the seismic effects of the COVID-19 pandemic, the biopharma industry continues to break new ground during a transformative era of product innovation.

J&J’s Janssen terminated its integrin research collaboration with Morphic Therapeutics. This follows the June 2022 termination of a partnership with AbbVie.

While the FTC’s proposed rulemaking would affect every industry, the impact it could have on biopharma and biotech companies is unique due to the technologically advanced and secretive nature of the research and information gathered and its value to other companies.

The announcement comes as the company awaits the FDA’s decision for Biogen and Japanese partner Eisai Co’s Alzheimer’s drug lecanemab.

Sanofi inked a research collaboration and license agreement with Stockholm, Sweden-based Salipro Biotech, whose proprietary platform enables researchers to improve workflows for developing therapeutic antibodies or small molecules that target membrane proteins. 

The scholarships will prioritize students from underrepresented groups, who have overcome disadvantages or are first generation to attend college. The research collaboration aims to develop new methods for delivering therapies to patients.